



Q2 RESULTS (AUGUST – OCTOBER 2020)

F.R. Martelet, M.D., CEO

9 December 2020

Forward-looking statement

IMPORTANT NOTICE

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Today's speakers



FRANCOIS MARTELET, M.D.,
Master's Degree Business
Chief Executive Officer



ROBERT MAIORANA
Acting Chief Financial Officer

Q2 Corporate Highlights

- **Sustained progress on Apealea with partner Elevar Therapeutics**
 - Agreement signed for commercialization in MENA
 - Global Named Patient Program initiated ex-US
 - Clear path set for regulatory submission in US with expanded clinical program (post period)
 - Initial prescriptions in Finland despite COVID-19 challenges
- **Our cost control program has enabled investment in the XR-18 and XR-19 technologies and preparation for docetaxel micellar Phase1b**
- **New Apealea and XR-17™ IP and trademark protection**
- **Continued strengthening of management and senior team**

Q2 Financial Highlights

- **Cash and cash equivalents & short-term investments TSEK 329,588 (29,039)**
 - Several one-off costs during the quarter:
 - MSEK 3.1 fine from NASDAQ
 - MSEK 3.4 write down due to reduced need for premises in Uppsala
 - TSEK -18,114 (-14,449) employee benefit expenses relating to staff redundancies
 - MSEK 4.1 due to amortization of capitalized development costs for Apealea/Paclical
- **Operating profit/loss TSEK -53,693 (-47,436)¹**
- **Net profit/loss after tax TSEK -53,538 (-18,309)¹**
- **Earnings per share SEK -0.12 (-0.06)^{1,2}**
- **Inventory increase of TSEK 20,514: from TSEK 28,837 Apr 30, 2020 to TSEK 49,351 Oct 31, 2020**

¹The comparison period has been recalculated to take into account the correction of errors in prior periods made during 2019/2020, see Note 4 in the 2019/2020 annual report.

²Earnings/loss per share for the comparison periods has been adjusted for the bonus issue component in the rights issue carried out during the 2019/2020 financial year.

Management and Senior Team strengthened



FRANCOIS MARTELET, M.D.,
Master's Degree Business
Chief Executive Officer



FREDRIK JÄRRSTEN MBA
Chief Financial Officer



PETER SELIN BSc
Chief Business Officer



ROBERT MAIORANA BSc
*Finance Manager (Current
Acting Chief Financial Officer)*

- **...plus, TWO Senior Scientists**

Building a portfolio based on XR-17™ platform technology

Product	Indication	Pre-clinical	Phase I	Phase II	Phase III	Registration / approval	Commercial Launch	Geography		
Human Health Portfolio										
Apealea® / Paclical® (paclitaxel)	Ovarian cancer							USA		
	Ovarian cancer							EU / EEA		
Docetaxel micellar	Prostate cancer						Global			
New API	Undisclosed								Global	
XR-19 (combination)	Assessments in various cancers								Global	
Animal Health Portfolio (Canines)										
Paccal vet (paclitaxel)	Mammary Carcinoma									USA
Doxophos vet (doxorubicin)	Lymphoma									USA

The 4 pillars of the Oasmia's strategy from 2021 onwards

1

Execute on Apealea
global partnership
with Elevar
Therapeutics

2

Partnering & clinical
development with
XR-17™ / XR-19
platforms

3

Clinical
development of
Docetaxel micellar
and new API(s)

4

In / out-licensing,
partnering & M&A
in oncology

Sustained progress on Apealea with Elevar Therapeutics

- **Global commercial partnering program progressing well**
 - Agreement signed with Taiba Middle East FZ LLC for Middle East and North Africa region.
 - Global named patient program initiated with Tanner ex-US where Apealea not yet commercially available
 - Elevar in active discussions with potential commercial partners including Europe & Asia, LatAm
- **Clear path set for US regulatory submission**
 - Several interactions with FDA since Elevar acquired rights to Apealea in March 2020
 - Elevar to complete two additional studies to support NDA filing
 - PK study aiming to initiate in H1 2021, expected to take approx. 12 months
 - Pivotal superiority study to investigate safety and efficacy of Apealea in epithelial ovarian cancer
 - Elevar working closely with The GOG Foundation to plan and execute global study starting H1 2021; expected duration 24-36 months to complete
- **Elevar exploring potential of Apealea in other indications**

Improving and investing in our technologies

XR-17™

- Specialist consultancy firm hired to drive partnering

XR-18


- R&D underway on next generation of XR-17™ solubilizing platform
- Work initiated to further improve and differentiate platform, with the ambition to enable improved versatility and broadening potential in novel long-term patent-protected medicines

XR-19

- Proof of-concept demonstrates XR-17™ allows for dual encapsulation
- Promising pre-clinical results show XR-19 has potential to deliver compounds in single i.v. administration
- Further internal studies underway including medical application assessment to identify possible indications and combinations

Docetaxel micellar poised for clinical development

1 in 7
men will be
diagnosed with
prostate
cancer



1.3m
men were newly
diagnosed with
prostate cancer
in 2018¹

- Docetaxel is approved for wide range of solid malignancies and standard of care for advanced prostate cancer
- Docetaxel micellar uses XR-17™, enabling IV administration of docetaxel without traditional solubility enhancers
- Swiss Group for Clinical Cancer Research (SAKK) due to initiate Phase Ib trial in the early 2021
- SAKK coordinates roughly 50 clinical trials each year to examine the efficacy of new cancer therapies



Investment bank hired to drive partnering of animal health portfolio

4

Paccal Vet

- A new XR-17™-based formulation of paclitaxel in development for the treatment of mastocytoma in dogs
- Results from Phase I and Phase II studies complete

Doxophos Vet

- A patented formulation of doxorubicin in combination with XR-17™ for the treatment of lymphoma, one of the most common forms of cancer in dogs
- Results from Phase I and Phase II studies complete

Dog cancer drug market appears to be concentrated in the USA and it is expected to grow substantially by 2025¹:



Recent progress made for each pillar of our strategy

1

Execute on Apealea global partnership with Elevar Therapeutics

Commercialization deal signed with Taiba for Apealea in MENA

Global named patient programme launched

Commercial partnerships in Europe, Asia and LatAm nearing completion

Generating resources to invest in pipeline growth

2

Partnering & clinical development with XR-17™ / XR-19 platforms

Evaluate poorly water-soluble products using XR-17™

Improved XR-17™ platform (XR-18) and XR-19 platform (for product combinations) in development

Proven development, regulatory and BD skills

3

Clinical development of Docetaxel micellar and new API(s)

Docetaxel micellar poised to enter Phase 1b clinical development, agreement signed with SAKK

New API in preclinical development

Large global market opportunities

4

In / out-licensing, partnering & M&A in oncology

Out-license or partner non-core assets (e.g. animal health portfolio)

In-licence oncology assets in clinical development

Agile, flexible structure, solid cash position

Looking ahead – multiple catalysts and investment drivers

Potential near and mid-term value drivers

- Elevar partnering for Apealea in Europe, Asia, LatAm
- SAKK docetaxel micellar Phase Ib initiation
- Partnering of Animal Health assets
- XR-19 lab proof of concept
- XR-18 platform development
- New XR-17™ oncology API to be disclosed
- M&A and in-licensing opportunities to build critical mass in oncology/spec pharma
- Partnering of XR-17™
- Apealea milestones and royalties

Investment drivers

- Commercial-stage company with proven capabilities
- Validated XR-17™ technology platform
- Growing oncology pipeline targeting large global markets
- Transformational global partnership
- Strong cash position
- Positioned for strong growth

